D. Boral Capital Issues Pessimistic Forecast for GeoVax Labs (NASDAQ:GOVX) Stock Price

GeoVax Labs (NASDAQ:GOVX) had its price target reduced by analysts at D. Boral Capital from $9.00 to $6.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

GeoVax Labs Stock Performance

GOVX stock opened at $0.40 on Wednesday. GeoVax Labs has a fifty-two week low of $0.40 and a fifty-two week high of $3.15. The company has a market capitalization of $11.91 million, a price-to-earnings ratio of -0.20 and a beta of 3.34. The business’s 50 day moving average price is $0.56 and its two-hundred day moving average price is $0.74.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07). GeoVax Labs had a negative net margin of 403.88% and a negative return on equity of 408.80%. Sell-side analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current year.

Hedge Funds Weigh In On GeoVax Labs

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in GeoVax Labs during the 1st quarter valued at $27,000. Armistice Capital LLC bought a new position in shares of GeoVax Labs during the third quarter valued at $253,000. Finally, Sabby Management LLC purchased a new stake in shares of GeoVax Labs during the third quarter valued at $313,000. 6.09% of the stock is owned by institutional investors.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.